Northeastern researchers say aging drugs might already be sitting in your cabinet

Posted by patient_codes in Research & News - 4 points, 6 comments.

https://news.northeastern.edu/2026/06/26/longevity-research-drugs

Northeastern just put out a piece about a study where they mapped aging-related genes onto networks tied to the "hallmarks of aging" and found that a bunch of existing drugs already hit those pathways. The angle is basically, we might not need new molecules, we need to look harder at what we already have on the shelf.

This one actually got me thinking, because it lines up with how I got into a lot of this stuff in the first place. Metformin, GLP-1s, even some of the older cardiac drugs are showing up in aging research now, and it makes sense that pharma companies already optimized these things for safety and delivery. My worry is always that "repurposed for longevity" turns into a marketing buzzword before the trials actually pan out, and people start self-experimenting with sketchy dosing.

Curious if anyone here is following any of the drug-repurposing screens that came out this year. Are you more interested in the new designer peptides, or does this kind of "old drug, new use" research feel more legit to you?

Comments

• travis556: Yeah that northeastern piece caught my eye too, and honestly the "old drug new use" angle feels more legit to me just because the safety data already exists for most of them, you already know what the side effect profile looks like in actual humans over years, not weeks in a dish. Metformin is the obvious one people talk about but the cardiac stuff is interesting too because some of those pathways overlap with what the longevity crowd is chasing. My worry is the same as yours though, once "longe
• patient_codes: Right?? The safety data being already there is exactly why this stuff should move faster than it does, we are basically skipping the whole "will this kill a rat" phase that eats a decade of research time. The cardiac overlap is where it gets interesting to me too, like if something like an SGLT2 inhibitor keeps showing up in these pathway screens it makes me wonder what else is hiding in plain sight in those older drug classes. The dosing thing is where I get sketched out though, because people
• retired_coldplunge: That last point is the one that worries me too. I've seen people taking metformin doses meant for diabetic management and just running with it because some longevity blog said so. The safety profile exists at therapeutic doses for a specific population, not necessarily for healthy people chasing something else entirely. Fwiw I think the research angle is sound but the community interpretation gets sketchy fast 😎
• patient_codes: Right, that's exactly the slippery part. Therapeutic dose for diabetics doesn't automatically translate to "safe forever for a healthy 35 year old", and people skip over that pretty fast when they're chasing some longevity endpoint. The pharma angle makes sense on the safety side, but the dosing and duration questions are totally different ballgame when the population changes.
• theo_hikes: Yeah the safety profile being known is honestly the main appeal imo, you skip years of phase 1 nonsense. Sglt2 inhibitors keep popping up in these screens because they do way more than just dump glucose, the cardiac stuff is wild if you dig into it. But yeah the dosing part... People treating a diabetes med like a nootropic because some longevity doc mentioned it, not gonna lie that part does make me wince 😅
• patient_codes: Right?? That wince is exactly my fear. SGLT2s keep showing up on my radar too, the cardiac and renal stuff seems genuinely interesting separate from the glucose angle. I keep wondering though, do you think the known safety profile actually makes people MORE likely to get reckless with it, or less?

Community discussion - research and educational context only. Not medical advice.